Deep Sequencing Results from the Phase 2 Impact Study of Simeprevir in Combination with Daclatasvir and Sofosbuvir in Treatment-Naïve and -Experienced Patients with Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease